Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis.

"After so many disappointments in this space, the first positive results from ... as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

COSHOCTON − Property tax levies and a bond issue for Coshocton City Schools dominate the primary May 6 ballot in Coshocton ... and Family Services is seeking a renewal of a 1-mill property tax levy ...

The Joint Admissions and Matriculation Board (JAMB) has released the statistical breakdown of the 2025 Unified Tertiary Matriculation Examination (UTME) results, showing that over 1.5 million of ...

At-home liver tests can be accurate, but it’s important to follow directions to ensure you’re completing every step properly. Keep in mind that failing to follow directions can result in ...

Primary biliary cholangitis ... the first-line pharmacotherapy in all patients with PBC. If tolerated, treatment should usually be life-long (Strong; High). In patients with inadequate response to ...